Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart scan strategy aims to slash cardiac events in rural china

NCT ID NCT07416344

Prevention Sponsor: Harbin Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a special heart CT scan to guide intensive treatment can reduce major heart problems like heart attacks and strokes compared to standard care. About 15,000 high-risk adults aged 40-75 in rural China will take part. The goal is to see if this personalized approach leads to fewer deaths and heart-related emergencies over 18 months, with a longer follow-up at 36 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 14,980 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion criteria of study villages: 1. Administrative villages 2. The village has no plans to merge with other villages within 3 years 3. The village is at least 2 kilometers away from other participating villages 4. The village has a sufficient number of study participants 5. The village is able to cooperate with the implementation of the study Inclusion criteria of study participants: 1. Men or women aged between 40 and 75 years 2. Live stably in the province where the study is conducted and no intention to migrate within next 3 years 3. Not participating in other clinical trials 4. Meet any of the following: (1)Low-Density Lipoprotein Cholesterol (LDL-C) ≥ 4.9 mmol/L or Total Cholesterol (TC) ≥ 7.2 mmol/L (2)Diabetes mellitus (3)Chronic Kidney Disease (CKD) Stage 3-4: estimated Glomerular Filtration Rate (eGFR) 15-59 mL/min/1.73m\^2 (4)With a history of hypertension and 3 risk factors, combined with LDL-C ≥ 1.8 mmol/L or TC ≥ 3.1 mmol/L \[Risk factors (assessed pre-intervention): smoking, low HDL-C, male ≥ 45 years old or female ≥ 55 years old\] (5)With a history of hypertension and 2 risk factors, combined with LDL-C ≥ 2.6 mmol/L or TC ≥ 4.1 mmol/L \[Risk factors (assessed pre-intervention): smoking, low HDL-C, male ≥ 45 years old or female ≥ 55 years old\] 5. Sign the informed consent Exclusion Criteria: 1. Unwillingness or inability to undergo coronary CTA examination (e.g., previous history of severe contrast allergy, claustrophobia, or inability to cooperate with scanning and breath-holding for physical reasons in study participants) 2. Typical angina symptoms, known coronary artery disease, or other major atherosclerotic cardiovascular disease 3. Known cerebrovascular disease (e.g., cerebral hemorrhage, cerebral infarction, etc. ) 4. Prior invasive or non-invasive coronary angiography within the last 5 years 5. Known familial hypercholesterolemia or other inherited disorders of lipid metabolism requiring lipid-lowering therapy 6. Presence of active bleeding or diseases with a very high risk of bleeding (e.g., active peptic ulcer disease, gastrointestinal pathologies with increased risk of bleeding, hematologic disorders with increased risk of bleeding, etc.) 7. End-stage diseases such as cirrhosis decompensation, with life expectancy \<3 years 8. Have a malignant tumor 9. Intolerance of all statins 10. Lipid-lowering treatment for \>2 years 11. Pregnant or breastfeeding, planning to become pregnant within the next 3 years 12. eGFR \<30 mL/min/1.73m\^2 13. Platelet count \<100×10\^9/L 14. Poor compliance, unable to cooperate with study investigators 15. Investigators consider unsuitable for participants selected for this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beidahuang Industry Group General Hospital

    Harbin, Heilongjiang, 150088, China

  • Beijing Peking University WBL Biotech Co., Ltd

    Beijing, Municipality of Beijing, 100080, China

  • DaQing Oilfield Hospital

    Daqing, Heilongjiang, 163001, China

  • Daqing Longnan Hospital

    Daqing, Heilongjiang, 163453, China

  • Hegang People Hospital

    Hegang, Heilongjiang, 154100, China

  • Heilongjiang Provincial Hospital, China

    Harbin, Heilongjiang, 150036, China

  • Hongqi Hospital Affiliated to Mudanjiang Medical University

    Mudanjiang, Heilongjiang, 157011, China

  • Jiamusi Central Hospital

    Jiamusi, Heilongjiang, 154002, China

  • Mudanjiang Cardiovascular Hospital, China

    Mudanjiang, Heilongjiang, 157011, China

  • Shuangyashan Shuangkuang Hospital

    Shuangyashan, Heilongjiang, 155100, China

  • The Baoquanling Hospital of Beidahuang Group

    Hegang, Heilongjiang, 154211, China

  • The First Affiliated Hospital of Jiamusi University, China

    Jiamusi, Heilongjiang, 154003, China

  • The First Hospital of Qiqihar

    Qiqihar, Heilongjiang, 161005, China

  • The First Hospital of Suihua City

    Suihua, Heilongjiang, 152000, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150086, China

  • The Third Affiliated Hospital of Qiqihar Medical University

    Qiqihar, Heilongjiang, 161000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.